



## **IDDS Presents Intranasal Ketamine Data at Premier Department of Defense Scientific Meeting**

### **Intranasal Ketamine shows superior pain relief at all doses versus placebo with no serious side effects or deterrent to vital signs or arterial oxygen saturation**

New York, NY, August 16, 2005 - Intrac, Inc. (OTC BB: ITRD) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS) is presenting data today on the use of intranasal Ketamine for acute pain at the Department of Defense's premier scientific event, the Advanced Technology Applications for Combat Casualty Care (ATACCC) 2005 Conference.

This year's meeting focuses on battlefield medical care issues during combat operations in support of Operation Iraqi Freedom and on the technologies available today and in the future that can be used to meet the increasingly complex medical needs of combat casualties.

"IDDS is focused on enhancing the available options for sufferers of moderate-to-severe acute pain," stated Daniel B. Carr, M.D., chief executive and chief medical officer of IDDS. "Intranasal Ketamine, a self-administered, needle-free, fast-acting pain reliever, is an ideal alternative to the traditional medic-administered morphine currently used on the modern battlefield."

#### About PMI-150

Intranasal Ketamine or PMI-150 is a patient-controlled nasal spray that delivers a metered dose of ketamine, a non-opioid analgesic used for treatment of moderate-to-severe pain. Ketamine's 30-year record as safe, effective and non-addictive with virtually no side effects makes it an ideal pain management solution.

#### About IDDS

IDDS is a specialty pharmaceutical company, applying innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.

Investor Contact:  
The Investor Relations Group  
Christie Mazurek / Ross D'Eredita  
(212) 825-3210

Media Contact:  
The Investor Relations Group  
Janet Vasquez  
(212) 825-3210

IDDS, Inc.  
June Gregg  
(212) 554-4550